58 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast PeerView

    • Science
    • 3.6 • 5 Ratings

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Ghassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

    Ghassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAU865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.

    Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This educational activity is supported through independent educational grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Autem Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Neogene Therapeutics; NewBridge Pharmaceuticals; Novartis Pharmaceuticals Corporation; Servier Laboratories; Tempus; Vector; and Yiviva.
    Grant/Research Support from Agenus Inc.; Arcus Biosciences, Inc.; AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio Therapeutics Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn Healthcare SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma Biotechnology, Inc.; QED Therapeutics; and Yiviva.


    Faculty/Planner
    Anthony El-Khoueiry, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Exelixis, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.; Qurient; and Senti Biosciences.
    Grant/Research Support from Astex Pharmaceuticals; AstraZeneca; Auransa Inc.; and Fulgent Pharma.


    Faculty/Planner
    Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and Pfizer.
    Grant/Research Support from Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer; and Tvardi Therapeutics.


    Faculty/Planner
    Stacey M. Stein, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Eisai Inc.; Exelixis, Inc.; and Genentech, Inc.
    Data Safety Monitoring Board for Aethlon Medical, Inc.and Genentech, Inc.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Planner
    Andrea Wilson Woods
    President & Founder, Blue Faery

    Andrea Wilson Woods has a financial interest/relationship or affiliation in the form of:
    Consultant for AstraZeneca and Humanise Health.

    • 1 hr 30 min
    Jonathan Corren, MD / Mario Castro, MD - Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment

    Jonathan Corren, MD / Mario Castro, MD - Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.

    Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an independent educational grant from AstraZeneca LP.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Co-Chair/Planner
    Jonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.
    Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.
    Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.


    Co-Chair/Planner
    Mario Castro, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.
    Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.
    Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.
    Stock Shareholder in Aer Therapeutics.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    • 50 min
    Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

    Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EGP865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024.

    Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through an educational grant from Bristol Myers Squibb.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.
    Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.
    Stock Shareholder in Inspirna, Inc.


    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    • 23 min
    Philip J. Mease, MD, MACR - Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care

    Philip J. Mease, MD, MACR - Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZQX865. CME credit will be available until November 2, 2024.

    Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care

    Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

    Support
    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

    Disclosures
    Philip J. Mease, MD, MACR, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie; ACELYRIN Inc.; Aclaris Therapeutics, Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Galapagos NV; Gilead Sciences, Inc.; GlaxoSmithKline; Inmagene; Janssen Pharmaceuticals, Inc.; Lilly; MoonLake Immunotherapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Sun Pharmaceutical Industries Ltd.; UCB, Inc.; Ventyx Biosciences, Inc.; and XinThera.
    Grant/Research Support from AbbVie.; ACELYRIN Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
    Speaker for AbbVie; Amgen; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB, Inc.


    M.E. Beth Smith, DO, MCR, FACP, has no financial interests/relationships or affiliations in relation to this activity.

    Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

    Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

    All of the relevant financial relationships listed for these individuals have been mitigated.

    • 34 min
    Boni Elizabeth Elewski, MD, Mark Lebwohl, MD - Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares

    Boni Elizabeth Elewski, MD, Mark Lebwohl, MD - Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares

    Go online to PeerView.com/NJA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP. Upon completion of this activity, participants should be better able to: Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations; Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis; Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action; and Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach

    • 58 min
    Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP / Peter A. Lio, MD - Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis

    Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP / Peter A. Lio, MD - Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis

    Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

    • 33 min

Customer Reviews

3.6 out of 5
5 Ratings

5 Ratings

Top Podcasts In Science

Hidden Brain, Shankar Vedantam
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
WNYC Studios
Alie Ward
Neil deGrasse Tyson
Sam Harris

You Might Also Like